Stockwinners Market Radar for July 10, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:44 EDT Meta Platforms exec sells $483K in common stock - In a regulatory filing, Meta Platforms disclosed that its General Counsel Jennifer Newstead sold 905 shares of common stock on July 9th in a total transaction size of $483K.

20:04 EDT Cathie Wood's ARK Investment buys 248K shares of PacBio today

20:02 EDT Cathie Wood's ARK Investment buys 766K shares of Blade Air Mobility today

19:48 EDT GAP Airports announces credit line refinancing for MXN1.0B - Grupo Aeroportuario del Pacifico announces that it completed the refinancing of the credit facility that matured today with Banco Nacional de Mexico, S.A., for Ps. 1.0 billion, extending the maturity by 12 additional months. The interest will be payable monthly at a variable rate of TIIE-28 plus 18 basis points, without fees, and principal payment on July 10, 2025.

19:17 EDT Hecla Mining reports Q2 silver production of 4.5M oz, up 6% from Q1 - "Hecla produced 4.5 million silver ounces during the quarter, an increase of 6% over the prior quarter, reflecting a full quarter of production at Lucky Friday with record throughput, improved throughput at Keno Hill and another solid performance by Greens Creek," said Cassie Boggs, Interim President and CEO. "At Keno Hill we continue to focus on improving the safety culture and environmental performance, positioning the mine for long term success and while our actions are starting to show positive results, more work is required at this operation. We are also in contact with and continue to monitor the positions of First Nation of Na-Cho Nyak Dun, on whose Traditional Territory Keno Hill is partly located. With Keno Hill's expected silver production to exceed 2.7 million ounces this year, Hecla is on track to produce about 17 million ounces in 2024, a nearly 20% growth rate from 2023, making Hecla the fastest growing established silver producer with production growth in the best geographical regions."

17:51 EDT Novo Nordisk gets FDA Complete Response Letter for once-weekly basal insulin - The company states: "Novo Nordisk announced that the FDA has issued a Complete Response Letter covering the Biologics License Application for once-weekly basal insulin icodec for the treatment of diabetes mellitus. In the letter, the FDA has requests related to the manufacturing process and the type 1 diabetes indication before the review of the application can be completed. Novo Nordisk is evaluating the content of the CRL and will work closely with the FDA to fulfil the requests. Novo Nordisk does not expect to be able to fulfil the requests during 2024. Novo Nordisk submitted the application for insulin icodec to the FDA in April 2023. In May 2024, an FDA Endocrinologic and Metabolic Drugs Advisory Committee meeting was convened with a panel of independent scientific experts to discuss the benefit-risk of once-weekly basal insulin icodec in type 1 diabetes. The panel determined that the data available were not sufficient to conclude on a positive benefit-risk in type 1 diabetes. The Advisory Committee did not discuss the use of once-weekly insulin icodec in type 2 diabetes. Insulin icodec is approved under the brand name Awiqli(R) in the EU, Canada, Australia, Japan and Switzerland for the treatment of both type 1 and type 2 diabetes and in China for the treatment of type 2 diabetes." Martin Lange, executive vice president for Development at Novo Nordis, stated: "We believe in the potential of once-weekly basal insulin icodec for those living with diabetes who require basal insulin therapy. We will work closely with the FDA to identify the next steps needed to complete the review so we can provide this novel treatment option to adults living with diabetes''.

17:49 EDT LL Flooring jumps over 20% after all three F9 nominees elected to board - Earlier on Wednesday, F9 Investments announced that, based on a preliminary tabulation of voting results, LL Flooring Holdings shareholders have elected all three F9 nominees-Tom Sullivan, Jason Delves, and Jill Witter-to serve as directors on LL Flooring's Board of Directors at the Company's 2024 Annual Meeting of Shareholders Sullivan stated: "We are deeply appreciative for the support our nominees received from LL Flooring's shareholders. As newly elected directors, we are committed to getting to work immediately and in close collaboration with our new Board colleagues." The final tabulation of voting results from LL Flooring's 2024 Annual Meeting will be disclosed by the Company in due course. Shares of LL Flooring Holdings closed up 21.4% or 12c to 68c per share.

17:36 EDT Federal Reserve Board fines Citigroup $60.6M for enforcement action breach - The Federal Reserve Board on Wednesday fined Citigroup $60.6M for violating the Board's 2020 enforcement action. Citigroup has made insufficient progress remediating its problems with data quality management and failed to implement compensating controls to manage its ongoing risk. The Board continues to monitor Citigroup's actions to comply with the 2020 action, which remains in effect. The Board's action is being taken in coordination with the Office of the Comptroller of the Currency. The penalties announced by the Board and the Office of the Comptroller of the Currency total approximately $135.6M. Reference Link

17:05 EDT Gladstone Commercial reports June-end portfolio occupancy of 98.5% - The company also states: "We continue to have ample liquidity and a strong capital structure. As of June 30, 2024, our available liquidity is approximately $48.8 million via our revolving credit facility and cash on hand."

17:02 EDT Distribution Solutions's Lawson Products to acquire Source Atlantic - Distribution Solutions "announced that its operating company, Lawson Products, under its affiliate Lawson Products Canada, Inc., signed an agreement to acquire Source Atlantic Limited. The transaction is expected to close in the third quarter of 2024, subject to regulatory approval and customary closing conditions. Source Atlantic, headquartered in Saint John, New Brunswick, Canada, is an industry-leading wholesale distributor of industrial MRO supplies, safety products, fasteners, and related value-add services for the Canadian MRO market. For the most recent fiscal year, Source Atlantic generated sales of approximately C$250M."

16:51 EDT Costco up 3% above $908 after June sales data, raised membership fee

16:46 EDT Orchid Island Capital sees July dividend 12c per share

16:34 EDT American States Water announces favorable ruling by CA Supreme Court - The company states: "American States Water announced that the California Supreme Court issued a ruling on July 8, 2024 that set aside a previously issued order by the California Public Utilities Commission in August 2020, which had mandated the discontinuation of an existing full revenue decoupling mechanism known as the Water Revenue Adjustment Mechanism used by investor owned water utilities since 2008 that, in conjunction with tiered rates, incentivizes water conservation. In response to the CPUC's order, AWR's regulated water utility, Golden State Water Company, three other investor-owned water utilities and the California Water Association each separately filed a petition in 2021 with the Court to review the CPUC's decision-making processes that resulted in discontinuing the use of the WRAM. As a result of the Court's decision, portions of the CPUC's August 2020 order, including the accompanying findings and conclusions that eliminated the water utilities' abilities to request the WRAM, are being vacated. To encourage water conservation, the CPUC in 2008 recommended that water utilities implement tiered rates, where customers pay more per unit of water used as they use more water. In exchange for implementing the tiered rates, the CPUC allowed water utilities, including GSWC, to "decouple" revenue from the amount of water sold and authorized the use of the WRAM. Since their implementation in 2008, the tiered rates and the WRAM have promoted conservation while mitigating fluctuations in GSWC's earnings due to changes in water consumption by its customers. In August 2023, GSWC filed a general rate case application for all its water regions and the general office that will determine new water rates for the years 2025 - 2027. Among other things, GSWC had requested the continuation of tiered rates and mechanisms to accommodate fully decoupled revenues and sales."

16:33 EDT Polestar discloses Nasdaq listing compliance notice - Polesta has received notice from the Nasdaq Stock Market LLC that the Company is not currently in compliance with the $1.00 minimum bid price requirement, as set forth in Nasdaq Listing Rule 5450(a)(1). The Notice indicated that, consistent with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 days, or until 2 January 2025, to regain compliance, by having the closing bid price of the Company's ADSs meet or exceed $1.00 per ADS for at least ten consecutive business days. If the Company does not regain compliance by the Compliance Deadline, the Company may be afforded an additional 180 calendar day period to regain compliance as provided by the Nasdaq Listing Rules.

16:32 EDT Granite's Lehman-Roberts selected as subcontractor on Tennessee project - Granite announced Lehman-Roberts, a Granite company, has been selected as a subcontractor by Dement Construction Company, LLC on a project for the Tennessee Department of Transportationin the ongoing infrastructure upgrade project where Interstate 22 terminates into State Route 4 and U.S. Route 78 southeast of downtown Memphis. Funded by Federal and TDOT funds, Lehman-Roberts' portion of the contract is approximately $21 million and will be included in Granite's second-quarter CAP.

16:31 EDT CMS proposes new reimbursement for Exparel in outpatient surgical enviroments - Pacira BioSciences announced that the Centers for Medicare and Medicaid Services CMS has issued its proposed Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System rule for 2025. In the proposed rule, EXPAREL or bupivacaine liposome injectable suspension, is one of six covered non-opioids-two of which are specific to ophthalmology- qualifying for separate Medicare reimbursement in both the ambulatory surgical center, ASC, and hospital outpatient HOPD settings. Pending finalization, this policy would go into effect beginning January 1, 2025..."Following several years of advocacy for reimbursement policy reform to allow increased patient and provider access to non-opioids, we are pleased to see EXPAREL included as one of only six qualifying non-opioid drugs to treat postsurgical pain in the proposed rule," said Frank D. Lee, Chief Executive Officer of Pacira. "As the only covered single-dose product approved for both local and regional analgesia across surgical procedures, we believe this new reimbursement-pending finalization-will offer clinicians increased ability to utilize a best-in-class option for achieving long-lasting non-opioid pain control with an increased ability to transition to the outpatient environment."

16:29 EDT Airbnb CEO sells $17.5M in common stock - In a regulatory filing, Airbnb disclosed that its CEO Brian Chesky sold 115.4K shares of common stock on July 8th in a total transaction size of $17.5M.

16:24 EDT Artisan Partners reports preliminary June AUM $158.9B - Artisan Partners reported that its preliminary assets under management as of June 30 totaled $158.9B. Artisan Funds and Artisan Global Funds accounted for $77B of total firm AUM, while separate accounts and other AUM accounted for $81.9B.

16:21 EDT AssetMark Financial reports Platform assets of $119.4B at June-end, up 18.5% - AssetMark Financial Holdings released its "AssetMark Monthly Knowledge" Report. Company results for the month of June 2024 include: Platform assets of $119.4B at the end of June, up 18.5% year-over-year. Morningstar Wealth TAMP assets are not included in our total as the deal has been signed, but is not closed. Net flows were $397M in the month of June, down 36.4% year-over-year. AssetMark Trust Company client cash was $2.93B, down 0.3% year-over-year. Number of households increased 5.4% year-over-year to 261,341 at the end of June.

16:17 EDT Horizon Technology reports Q2 new loan originations at $11.5M - Horizon Technology provided its portfolio update for the second quarter ended June 30, 2024 and an update on the lending platform of Horizon Technology Finance Management LLC ("HTFM"), its investment adviser. During the second quarter of 2024, HRZN funded a total of $11.5 million of loans and $0.5 million of equity, as follows: $5.0 million to a new portfolio company, a fulfillment and supply chain technology services company focused on optimizing logistics across a variety of industries. $5.0 million to an existing portfolio company, Supply Network Visibility Holdings LLC (d/b/a Everstream Analytics), a provider of supply chain risk management software. $1.0 million of debt and $0.5 million of equity to an existing affiliated portfolio company, a builder of conservation memorial forests that offer sustainable alternatives to cemeteries. $0.5 million to an existing portfolio company, Nexii Building Solutions Inc., a green construction technology company focused on creating environmentally-friendly, durable, cost-efficient and disaster-resilient buildings.

16:16 EDT Zurn Elkay Water names Dave Pauli as new CFO - Zurn Elkay Water So announced the promotion of Dave Pauli to the position of Chief Financial Officer. Pauli will oversee all aspects of Zurn Elkay's financial operations effective immediately including financial planning and analysis, treasury, reporting, tax, internal audit and investor relations. The promotion comes as Mark Peterson, who joined the company in 2006 and has served as CFO since 2011, becomes the company's Chief Administrative Officer, overseeing human resources, enterprise risk, real estate and facilities management, and environmental health and safety.

16:12 EDT Sanofi ships U.S. influenza vaccines for the 2024/25 season - Sanofi started shipping its first influenza vaccines across the U.S. in preparation for the 2024/25 flu season. Following this first shipment, additional shipments of the full Sanofi flu vaccine portfolio will continue through October to healthcare provider offices, pharmacies and other immunizers to support fall immunization campaigns. With over 125 years of heritage in helping protect global public health, Sanofi is a world leader in vaccines, helping to vaccinate more than 500 million people annually. All flu vaccines provided by Sanofi to the US market are trivalent, meaning they offer protection against the current three strains of influenza (two influenza A strains and one influenza B strain). These strains were selected based on a collaborative review of influenza surveillance by the U.S. FDA, World Health Organization, the Centers for Disease Control and Prevention, among other public health experts, as the strains most likely to cause illness in the upcoming flu season.

16:09 EDT Nikola regains Nasdaq listing compliance - On July 10, 2024, Nikola received written notice from The Nasdaq Stock Market LLC informing the Company that it has regained compliance with Nasdaq Listing Rule 5450(a)(1), which requires that companies listed on the Nasdaq Global Select Market maintain a minimum bid price of $1.00 per share. Nasdaq notified the Company in the Compliance Notice that, from June 25, 2024 to July 10, 2024, the closing bid price of the Company's common stock had been $1.00 per share or greater and, accordingly, the Company had regained compliance with Nasdaq Listing Rule 5450(a)(1) and that the matter was now closed.

16:06 EDT Bassett Furniture integrates Domo throughout its operations - Domo (DOMO) announced that Bassett Furniture (BSET) integrates Domo throughout its operations - from corporate headquarters to retail stores and its distribution team - to power data-driven decisions. Bassett Furniture started working with Domo in 2020 and now uses real-time data to engage retailers, select the right merchandise for a specific region, reduce unnecessary inventory and maximize retail space. "We wanted something that would enable us to walk into any store and have complete insight into the performance of any employee, furniture item or time period," said Brian Claspell, CIO at Bassett Furniture. "Domo's an incredible tool because it provides data in a succinct way that allows us to look across product lines and customer bases. This helps us understand our customers better so we can provide a better experience."

16:06 EDT Bassett Furniture announces restructuring plan - The company also announced a restructuring plan to more right-size its cost structure. The five-point plan includes: Driving organic growth through Bassett-branded retail locations, omni-channel capabilities, and enhanced customization positioning to expand dedicated distribution footprint. Rationalizing U.S. wood manufacturing from two locations into one primary location, supported by a small satellite operation. Optimizing inventory and dropping unproductive lines. Improving overall cost structure and invest capital in refurbishment of current retail locations. Lastly, closing the Noa Home e-commerce business. "Bassett Furniture has a long history of weathering economic cycles, such as the inflationary environment and slow housing market we're experiencing in 2024 - factors that led to soft demand in our second quarter," explained Spilman. "The business climate has remained difficult through the first six months of this year and may not improve in the near future. Accordingly, we are committed to returning to profitability by running a leaner operation, with priority focus on both our inventory position and the overall cost structure. We believe that our restructuring plan, expected to improve our bottom line between $5.5 million and $6.5 million on an annual basis, coupled with our solid balance sheet, puts us in a position to be a considerably stronger company when customer demand inevitably improves. I'm particularly pleased that our Board believes in our ability to improve operations and continue our strong cash generation by increasing our quarterly dividend by 11%."

16:04 EDT PriceSmart reports 54 warehouse clubs in operation as of May 31 - The company had 54 warehouse clubs in operation as of May 31, 2024 compared to 51 warehouse clubs in operation as of May 31, 2023.

16:01 EDT Cognyte gets $10M follow-on order from EMEA customer - Cognyte Software announced a $10 million follow-on order from a national security agency, a long-term Cognyte customer in the Europe-Middle East-Africa region. This follow-on order enables the customer to derive additional value by extracting more insights from their constantly growing data volumes.

15:08 EDT Sanofi treatment of myotonic dystrophy type 1 designated for orphan status - A nonreplicating adeno-associated virus, serotype SAN011, that expresses an artificial microRNA which reduces and degrades the DMPK mRNA trapping the RBPs was granted orphan designation as a treatment of myotonic dystrophy type 1, according to a post the FDA website. Sanofi US Services is listed as the sponsor. Reference Link

14:39 EDT Where Food Comes From Inc trading halted, volatility trading pause

14:21 EDT HubSpot trading halted, volatility trading pause

14:17 EDT Sight Sciences up 11% after Piper positive on CMS reimbursement proposal

13:38 EDT Lantheus 'welcomes' CMS' proposed CY25 OPPS rule - Lantheus Holdings announced that it "welcomes" the Centers for Medicare & Medicaid Services' Proposed Medicare Hospital Outpatient Prospective Payment System, or OPPS, Rule for calendar year 2025 for improved payment for specialized diagnostic radiopharmaceuticals to support patient access for Medicare beneficiaries. "Today, CMS shared its proposed refinements to the existing packaging policy to improve the accuracy of the overall payment amounts by paying separately for any diagnostic radiopharmaceutical with a per day cost greater than $630. Under current OPPS rules, the costs associated with diagnostic radiopharmaceuticals are packaged into the payment for the nuclear medicine tests. In the proposed rule, innovative diagnostic radiopharmaceuticals, including PYLARIFY, would continue to be paid separately by CMS for traditional Medicare Fee for Service patients in the hospital outpatient setting following the expiry of traditional pass-through payment status. Proposed rules are published annually and will have a 60-day comment period, which will end on September 9, 2024. The final rule will be issued in early November and take effect January 1, 2025," the company stated. Brian Markison, Chief Executive Officer of Lantheus, added: "At Lantheus, we advocate for equitable access to advanced diagnostic radiopharmaceuticals to aid providers in diagnosing and staging disease, ultimately leading to better patient outcomes. We are pleased that the proposed rules recognize the value of diagnostic radiopharmaceuticals, including PYLARIFY, and the need to change the current payment system. We will work with coalition partners and advocates to enact separate payment for 2025, while continuing to implement multi-faceted strategies to maintain patient access."

13:19 EDT Rite Aid, Elixir agree to pay $101M to resolve false reporting rebate claims - The Justice Department announced that Rite Aid Corporation and Rite Aid subsidiaries, Elixir Insurance Company, RX Options LLC and RX Solutions LLC, have agreed to resolve allegations that they violated the False Claims Act by failing to accurately report drug rebates to the Medicare Program. As part of the settlement, Elixir Insurance and Rite Aid will pay the United States $101M, and RX Options and RX Solutions will grant the United States an allowed, unsubordinated, general unsecured claim for a total of $20M in Rite Aid's bankruptcy case pending in the District of New Jersey. The settlement is based on the companies' ability to pay and was approved on June 28 by the bankruptcy court as part of Rite Aid's plan of reorganization, which is expected to become effective later this summer. In addition to operating one of the country's largest retail pharmacy chains, Rite Aid offered Medicare drug plans and pharmacy benefits manager services through Elixir Insurance, RX Options and RX Solutions. "Participants in Medicare's drug program must accurately report price concessions, including drug manufacturer rebates, to ensure that the government receives the benefit of those concessions," said Principal Deputy Assistant Attorney General Brian M. Boynton, head of the Justice Department's Civil Division. "Today's settlement reflects the Justice Department's commitment to hold accountable entities that pursue their own financial interests at the expense of taxpayer programs." Reference Link

12:59 EDT Amazon announces AWS App Studio to help build applications - Amazon Web Services announced AWS App Studio, a generative artificial intelligence-powered service that uses natural language to create enterprise-grade applications. "A user simply describes the application they want, what they want it to do, and the data sources they want to integrate with, and in just minutes, App Studio builds an application that could have taken a professional developer days to build from scratch," AWS said.

12:39 EDT CVRx extends drop to 9% after Canaccord research note

12:20 EDT Apple up 3% to $232.32 after Bloomberg report on iPhone shipment plans

12:12 EDT Wex secures preliminary injunction against HP Inc. - WEX (WEX) has obtained a preliminary injunction to stop the infringing conduct of HP Inc. (HPQ) and Hewlett-Packard Development Company, L.P. and to protect the WEX brand. Despite WEX's decades of use of the WEX name, in March 2024, HP announced the launch of its own "WEX," a misappropriation of WEX's trademarks. WEX filed a federal lawsuit against HP on April 11, 2024, and moved for a preliminary injunction one day later. After hearing argument by the parties on July 1, 2024, Judge John A. Woodcock, Jr. of the United States District Court for the District of Maine issued an opinion on July 9, 2024 granting in full the preliminary injunction against HP that WEX requested. As the Court held in ruling that WEX was likely to succeed on the merits of its claim that HP's conduct infringed WEX's trademarks, "the evidence favoring WEX is overwhelming." "We are pleased that the Court recognized that HP's use of the 'WEX' name would inevitably cause confusion in the marketplace, and put a stop to HP's infringing conduct," said Sara Trickett, Chief Legal Officer at WEX. "WEX is committed to protecting the WEX brand and our customers from the confusion caused by HP's actions. We look forward to obtaining a permanent injunction at trial."

12:00 EDT Hudson Pacific falls -12.3% - Hudson Pacific is down -12.3%, or -63c to $4.52.

12:00 EDT Hawaiian Electric rises 14.9% - Hawaiian Electric is up 14.9%, or $1.28 to $9.85.

12:00 EDT Solaris Oilfield rises 31.9% - Solaris Oilfield is up 31.9%, or $2.64 to $10.91.

11:21 EDT Marsh McLennan increases quarterly dividend 15% to 81.5c per share - The Board of Directors of Marsh McLennan declared a 15% increase in the quarterly dividend from 71c to 81.5c per share on outstanding common stock, payable on August 15, to stockholders of record on July 25.

10:22 EDT Select Medical, UPMC to open inpatient rehabilitation hospital - Select Medical and UPMC announced plans to open Helen M. Simpson Rehabilitation Hospital - West Shore in 2Q25. A satellite of its namesake, the acute inpatient rehabilitation hospital will serve the needs of the growing Central Pennsylvania West Shore region. The 20-bed hospital-in-a-hospital will feature a state-of-the-art therapy gym and advanced rehabilitation technologies to treat patients recovering from stroke, spinal cord and brain injury, amputation, neurological disorders and orthopaedic conditions. The rehabilitation hospital will be housed in the newly renovated fifth floor of UPMC West Shore on UPMC's growing West Shore campus located just off I-81 and the Carlisle Pike on Technology Parkway in Mechanicsburg. UPMC West Shore is a five-story, 166-bed acute care hospital with all private rooms that provides nationally accredited comprehensive cancer care, premier orthopaedic and spine care, the region's leading thoracic and surgical care, and a complement of multi-specialty outpatient services.

10:08 EDT Lantheus jumps 26% to $97.86 after Medicare payment proposal

10:01 EDT MarineMax rises 10.1% - MarineMax is up 10.1%, or $3.08 to $33.44.

10:01 EDT Solaris Oilfield rises 26.8% - Solaris Oilfield is up 26.8%, or $2.22 to $10.49.

10:00 EDT Dutch Bros falls -5.9% - Dutch Bros is down -5.9%, or -$2.43 to $38.82.

10:00 EDT Annovis Bio falls -11.3% - Annovis Bio is down -11.3%, or -$1.64 to $12.93.

09:47 EDT Carvana rises 5.9% - Carvana is up 5.9%, or $7.40 to $133.10.

09:47 EDT Euronav NV falls -4.6% - Euronav NV is down -4.6%, or -77c to $15.96.

09:47 EDT Annovis Bio falls -6.2% - Annovis Bio is down -6.2%, or -90c to $13.67.

09:40 EDT Beacon completes acquisition of Roofers Mart of Southern California - Beacon has completed the acquisition of Roofers Mart of Southern California, located in Walnut, California. Roofers Mart has a 40-year history serving roofing contractors in the Los Angeles metro market. Beacon continues to drive above market growth via footprint expansion with seven acquisitions to date in 2024.

09:34 EDT Tempus AI surpasses 500 research publications - Tempus AI has reached a research milestone of over 500 research publications. In the last eight years, Tempus has invested in rigorous scientific research to validate its diagnostic offerings, while also working with biopharma and academic collaborators to publish research supported by the company's multimodal data library. This research milestone includes published and/or acknowledged work, comprised of: 143 peer-reviewed articles, of which 106 were Tempus-authored; 291 poster presentations based on clinical and research data presented at major scientific conferences; and 31 oral presentations at scientific meetings such as the American Society of Clinical Oncology Annual Meeting, San Antonio Breast Cancer Symposium, Society for Immunotherapy of Cancer Annual Meeting, and American Heart Association's Scientific Sessions.

09:24 EDT Biotricity launches cardiac monitoring pilot program wih hospital group - Biotricity announced the launch of a new cardiac monitoring pilot program with a prominent hospital group encompassing 60 sites spread across multiple states. Building on the momentum of previous pilot programs, Biotricity will collaborate closely with healthcare professionals at these 60 sites to enhance patient interaction protocols and optimize data collection processes. This latest pilot program aims to demonstrate the transformative potential of Biotricity's advanced technology suite in improving cardiac patient outcomes and streamlining healthcare delivery across a broader geographic region.

09:10 EDT American Rebel Beer surpasses 100 retail locations throughout Kansas - American Rebel Holdings provided an update on the availability of its American Rebel Beer as it continues to work with its distribution partners to increase the number of locations consumers can purchase their premium light lager. "We are proud to announce that American Rebel Light Beer, our patriotic domestic light lager, is available at over 100 fine establishments across Kansas and growing quickly," said Andy Ross, Chief Executive Officer of American Rebel. "The feedback so far has been tremendous for American Rebel Beer after recently being featured at the Country Stampede.

09:09 EDT LPL Financial: Integrity Financial joins broker-dealer, RIA, custodial platforms - LPL Financial announced that financial advisors Justin Gore, J.D., and Michael Fusco, CRPC, have joined LPL Financial's broker-dealer, RIA and custodial platforms to launch a new independent practice, Integrity Financial Group. They reported serving approximately $475 million in advisory, brokerage and retirement plan assets and join LPL from Ameriprise. The advisors are longtime friends who teamed up in 2021 to expand their services and grow their presence throughout South Carolina's Lowcountry. Based in the coastal town of Mount Pleasant, Gore has 26 years of experience in the financial services industry and oversees a range of specialized services including retirement strategies, estate planning and tailored financial planning. Fusco works out of the Myrtle Beach office and has 12 years of experience providing tailored wealth management and investment strategies for individuals and businesses.

09:08 EDT Neo-Concept announces joint venture agreement with Liwa Trading Enterprises - Neo-Concept International announced the formalization of a Joint Venture Agreement, JVA, with Liwa Trading Enterprises, a leading retail group headquartered in the United Arab Emirates, UAE. This joint venture aims to distribute and sell apparel products across the UAE and the Middle East and North African, MENA, regions. Effective July 8, 2024, the JVA solidifies the terms and conditions outlined in the Memorandum of Understanding dated May 21, 2024, previously announced. The agreement further delineates the operational and financial frameworks necessary for the establishment of the joint venture, JV, company. Under the JVA, NCI and Liwa will leverage their combined strengths to enhance the market presence of apparel products and services in the MENA region, including countries such as UAE, Saudi Arabia, Kuwait, Bahrain, Qatar, Oman, and other Northern African nations.

09:08 EDT AMD to acquire Silo AI in $665M all-cash transaction - AMD announced the signing of a definitive agreement to acquire Silo AI, the largest private AI lab in Europe, in an all-cash transaction valued at approximately $665 million. The agreement represents another significant step in the company's strategy to deliver end-to-end AI solutions based on open standards and in strong partnership with the global AI ecosystem. The Silo AI team consists of world-class AI scientists and engineers with extensive experience developing tailored AI models, platforms and solutions for leading enterprises spanning cloud, embedded and endpoint computing markets. Silo AI CEO and co-founder Peter Sarlin will continue to lead the Silo AI team as part of the AMD Artificial Intelligence Group, reporting to AMD senior vice president Vamsi Boppana. The acquisition is expected to close in the second half of 2024. Based in Helsinki, Finland, with operations in Europe and North America, Silo AI specializes in end-to-end AI-driven solutions that help customers integrate AI quickly and easily into their products, services and operations. Their work spans diverse markets, with customers including Allianz, Philips, Rolls-Royce and Unilever. Silo AI also creates open source multilingual LLMs, such as Poro and Viking, on AMD platforms in addition to its SiloGen model platform.

09:06 EDT Motorsport reports preliminary Q2 net income $1.6M-$1.8M vs ($8.2M) last year - Stephen Hood, CEO of Motorsport Games, stated, "These preliminary results reflect our focused strategy aimed at strengthening our financial position by reducing costs, streamlining operations and focusing on enhancing shareholder value. Our team is dedicated to sustaining this positive trajectory and furthering our concerted efforts in the racing game market with Le Mans Ultimate and our partnership with Kindred Concepts."

09:03 EDT Archer Daniels appoints Monish Patolawala as CFO - ADM (ADM) announced the appointment of Monish Patolawala as executive VP and CFO, effective August 1, succeeding Ismael Roig, who has been serving as ADM's interim CFO since January. Patolawala brings to ADM more than 25 years of experience overseeing global finance and technology teams across industrial and healthcare companies. Patolawala most recently served as President and CFO of 3M Company (MMM).

09:02 EDT Wix.com approves $200M repurchase program - Wix.com announced that its Board of Directors authorized a program to repurchase the Company's securities in an amount up to $200M. This repurchase program, in addition to the more than $1B of aggregate share repurchases executed by the Company since 2021, demonstrates the Board's continued confidence in the Company's ability to drive strong cash flow generation and ongoing commitment to increasing shareholder value.

08:49 EDT Alarum sees Q2 revenue over $8.8M, up 25% year-over-year - Based on a preliminary, unaudited review, Alarum anticipates reporting Strong performance for the first half and second quarter of 2024, highlighting accelerated operating and business growth: Revenue for the first half of 2024 is estimated at $17.2 million, representing an estimated increase of more than 35% compared to the same period in 2023. Revenue for the second quarter of 2024 is estimated at more than $8.8 million, representing the highest quarterly revenue achievement to date and an estimated increase of 25% compared to the same period in 2023. In the first half of 2024, the Company is estimated to have generated approximately $6.3 million in cashflow from operating activities, compared to a negative cashflow of approximately $0.1 million for the same period in 2023. In the second quarter of 2024, the Company is estimated to have generated approximately $3.1 million in cashflow from operating activities, including annual commission payments for the sales teams following meeting their targets for 2023 revenues, compared to a negative cashflow of approximately $0.3 million for the same period in 2023. Cash and cash equivalents balance as of June 30, 2024, amounted to approximately $21.7 million. NetNut's first half revenues are estimated at $16.7 million, a growth of more than 95% in the first half of 2024 compared to the equivalent period in 2023. NetNut's revenues for the second quarter of 2024 are estimated at $8.6 million, a growth of approximately 70% compared to the equivalent period in 2023. "The preliminary results for the first half of 2024 highlight our ability to deliver strong performance and value to our shareholders," said Shachar Daniel, CEO. "Our revenues and operating cashflow reflect the dedication of our team and the robustness of our business model. We remain committed to delivering innovative solutions and exceptional service to support the achievement of our future plans. Our strong cash position enables us to invest strategically in our future, to facilitate long-term success for Alarum and its stakeholders."

08:47 EDT Wiley appoints Matthew Kissner as permanent CEO - Wiley announced that its board of directors has appointed Matthew Kissner as president and CEO, following a successful interim period.

08:41 EDT Open Lending partners with Securian Financial - Open Lending announced a partnership with Securian Financial. The partnership enables Open Lending to provide insurance coverage through its Lenders Protection program as market volatility compromises automotive loan portfolios.

08:40 EDT Parker-Hannifin appoints E. Jean Savage to its board of directors - Parker Hannifin Corporation (PH) announced the election of E. Jean Savage to its Board of Directors, effective July 10, 2024. Savage is currently President and Chief Executive Officer of Trinity Industries (TRN), a leading provider of rail transportation products and services in North America, a position she has held since 2020.

08:39 EDT Lantern progresses toward diagnostic for LP-184 for oncology clinical trials use - Lantern Pharma announced a significant advancement towards the development of a diagnostic for its drug candidate LP-184. The diagnostic is currently based on qRT-PCR technology and is focused on quantifying the amount of PTGR1 RNA in patient tumor samples to assess the potential for sensitivity to Lantern's drug candidate LP-184. The company plans to further develop and validate the assay for its use as a potential tool for patient selection in later stage clinical trials across a broad range of solid tumors that have shown sensitivity to LP-184.Lantern has successfully confirmed PTGR1 as a key biomarker that it intends to use to optimize patient selection based on potential tumor sensitivity to the drug candidate LP-184. LP-184 is a precision oncology drug candidate with the potential to address multiple solid tumors. This confirmation marks a crucial step towards the development of a companion diagnostic and potential stratification tool to assist with targeted patient selection. Lantern plans on further validations and development of the assay using qRT-PCR and partnering with central labs and cancer centers for eventual use in patient selection and stratification. In a key publication on the utility and value of biomarkers in oncology trials among some of the most common cancers, titled Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis by Parker, et al., 2021 in Cancer Medicine found success of clinical trials to be significantly correlated to the incorporation of biomarkers. In particular, the Parker, et al. publication stated that: "...Our overall analysis of these four cancers, independent of indication, revealed a fivefold benefit of hazard ratios from the Markov models, suggesting a substantial benefit from biomarker use. The hazard ratio analysis of the Markov biomarker models examined how likely clinical trial success was associated with biomarker use versus no biomarker use.

08:38 EDT Cematrix announces $9.7M in new contracts - CEMATRIX has executed $9.7 million in new contracts since the company's last announcement. Factoring in the $9.7 million, the year-to-date total in contracts executed is $35.8 million.

08:37 EDT BTCS announces the launch of ChainQ - BTCS announces the launch of ChainQ, its blockchain analytics platform designed to revolutionize the exploration and comprehension of certain blockchain data. ChainQ represents a significant leap forward in simplifying the access, querying, and analysis of blockchain data, empowering users with unprecedented accessibility and insights. "ChainQ signifies our commitment to innovation in the blockchain space," said Charles Allen, CEO of BTCS. "We're thrilled to introduce this cutting-edge platform that merges the power of artificial intelligence with advanced search functionalities to offer users an intuitive and comprehensive solution to navigate blockchain data. The initial beta version of ChainQ supports indexed data from the Cosmos blockchain network. While we are launching with data from Cosmos, a smaller blockchain by market cap, its complexity sets the stage for expansion into larger and less complex chains with more holders and broader market awareness. As global cryptocurrency ownership increased by 34% in 2023, rising from 432 million in January 2023 to 580 million in December 20231, we see a vast and growing addressable market for our solutions."

08:34 EDT Ostin Technology announces success of crowdfunding campaign - Ostin Technology Group announces that the crowdfunding campaign launched by its subsidiary Pintura.Life has achieved remarkable success on the Indiegogo platform. Pintura managed to raise nearly $100,000 in just two months since the campaign launch in March, an impressive achievement showing the high level of consumer enthusiasm for Pintura's products in the North American market. In China, online sales of Pintura products have also seen encouraging outcomes. "We are deeply grateful to all the backers who supported Pintura's crowdfunding campaign. Their support and feedback have strengthened our resolve to expand in the US market," said Tao Ling, CEO and Chairman of the Company. "Going forward, we will introduce Pintura to more e-commerce platforms around the globe and anticipate revenue growth in the second half of 2024, while also working to penetrate the European and other overseas markets."

08:33 EDT Moleculin Biotech completes End of Phase 2 meeting with FDA for Annamycin - Moleculin Biotech announced the completion of its End of Phase 2, or EOP2, meeting with the FDA for its Phase 1B/2 clinical trial evaluating Annamycin in combination with Cytarabine for the treatment of subjects with AML as both first line therapy and for subjects who are refractory to or relapsed after induction therapy, or MB-106. The Company expects to report outcomes from the EOP2 meeting upon receipt of official minutes from FDA which is expected by the end of Q3. The EOP2 meeting was supported by second-line treatment results from the Company's ongoing MB-106 clinical trial. As recently reported on June 14, 2024, a total of 22 subjects have been enrolled, 20 of whom have completed efficacy evaluations with 9 subjects, or 45%, achieving a composite complete remission, consisting of 8, or 40%, subjects with complete remission, or CR, and one subject with complete remission with an incomplete recovery of peripheral blood counts, or CRi, following treatment with AnnAraC. Efficacy outcomes for 2 additional subjects (enrolled and treated) are pending. Of the 10 ITT subjects for whom AnnAraC was administered in the 2nd line setting, 5 achieved a CR, or 50%, and 6 achieved a CRc, or 60%. Of the 13 subjects in the ITT evaluable population that were 1st or 2nd line treatment, 7 achieved a CR, or 54%, and 8 achieved a CRc, or 62%. The mDOR for the 9 subjects who achieved a CRc is approximately 7 months and climbing.

08:32 EDT JanOne announces strategic realignment, including name change - JanOne has announced plans to enhance stockholder value through a visionary strategic realignment, entailing a redeployment of biotech assets and a change of its name. The plan, unanimously approved by the company's board and following the May acquisition of fintech innovator, ALT5 Sigma, is intended to complete a strategic review with the goal of monetizing the company's biotech assets. The company will explore a variety of alternatives that could include a partial or full spin-off, entry into one or more strategic alliances, or negotiation of a partial or full sale, while focusing on the recently acquired, ALT5 Sigma fintech as the company's core engine for revenue growth. Tony Isaac, JanOne's CEO, stated "the company's strategy continues to be to enhance value for stockholders both from the recent ALT5 acquisition and the potential monetization of the biotech assets. In the short few weeks since closing the ALT5 acquisition, we have seen a significant increase in the funnel of opportunities for ALT5, which made the decision to increase the focus on that business an easy one." Adding, "We are taking advantage of our strategic options and continuing to move swiftly toward unlocking the full potential of both sides of our company." In connection with the realignment, the company will change its name from JanOne Inc. to ALT5 Sigma Corporation. Its ticker symbol will change from "JAN" to "ALTS". Further, the company will change its website address from "janone.com" to "alt5sigma.com." The company will provide the timing of these changes in a subsequent press release. In May, the company completed the acquisition of blockchain fintech provider, ALT5 Sigma Inc., and its subsidiaries. ALT5 provides next generation blockchain-powered technologies to enable a migration to a new global financial paradigm through ALT5 Pay, a crypto-currency payment gateway, and ALT5 Prime, an electronic over-the-counter trading platform. As previously announced last August for its biotech business, the company was awarded a US patent for its innovative formulation of low-dose naltrexone, Jan123, for treating pain. Vay Tham, JanOne's Chief Revenue Officer and President of ALT5 Sigma, Inc., its wholly-owned subsidiary, commented, "Today's changes highlight the growing opportunities we see within JanOne. By seeking to uncouple the two businesses, each with their own unique opportunities and requirements, they will be able to reach their true market potentials without constraints." Marking the new strategic actions, JanOne CEO Isaac observed, "While our biotech's trajectory stays on track, we have diversified into fintech for the benefit of our stockholders. We have proven again that we can move quickly, which is the attribute of having an innovative leadership team and a nimble company that responds quickly to opportunities that become available to us. We continue to work in this manner toward our goal of unlocking stockholder value."

08:19 EDT ParaZero receives ASTM F3322-22 standard approval - ParaZero Technologies has received ASTM F3322-22 approval, following the completion of the official testing for its SafeAir Mavic 3 system. Using the Company's SafeAir system, operators of DJI Mavic 3 Series, will be eligible for an approval to fly over people and moving vehicles. These standards ensure consistent performance and set the safety requirements across various industries. The ASTM F3322-22 standard specifically pertains to the deployment of parachutes for Small Unmanned Aircraft Systems, ensuring their safe descent in the event of an emergency. The testing was monitored and approved by a third-party, unbiased testing agency. This agency meticulously measured, monitored and documented all relevant metrics, ensuring that every aspect of the testing process is conducted according to the highest standards.

08:16 EDT GameSquare sees $18M of annualized savings associated with FaZe Clan acquisition - $18 million of annualized cost savings associated with the FaZe Clan acquisition are expected, with the majority of these costs anticipated being removed during the second and third quarters of 2024; Management anticipates sequential quarterly improvements to profitability throughout 2024, supported by sales growth, gross margin improvement, and the benefit of cost saving initiatives.

08:13 EDT Ocuphire Pharma to highlight APX3330 at ARVO SIG panel, ASRS meeting - Ocuphire Pharma announced it will participate in the Association for Research in Vision and Ophthalmology Special Interest Group, ARVO SIG, panel and the American Society of Retina Specialists, ASRS, 42nd Annual Scientific Meeting, to highlight the potential of its lead oral candidate in development for diabetic retinopathy, DR. APX3330 is an oral small-molecule inhibitor of Ref-1 being developed for the treatment of non-proliferative diabetic retinopathy. DR affects approximately 10 million of the 38 million Americans with diabetes and is the leading cause of blindness in working-age adults. Ocuphire's Chief Executive Officer, George Magrath, M.D., M.B.A., M.S., will participate in an ARVO SIG panel discussion, "Oral Medications for the Management of Retinal Diseases." The discussion will focus on the potential of oral medications in treating retinal diseases earlier in the disease process, the need to develop new therapies with differentiated mechanisms of action, and the challenges and opportunities associated with developing these oral medications.

08:12 EDT Twist Bioscience announces launch of CHO Express Antibodies - Twist Bioscience announced the expansion of its high-throughput antibody portfolio with the launch of a CHO cell line for Twist Express Antibodies. Twist also offers HEK293 expression Twist Express Antibodies. "With the majority of biotherapeutic drugs manufactured in CHO cell lines, expressing small-scale therapeutic antibody candidates in CHO for screening has become a vital first step to ensure successful downstream scale-up. We now provide a comprehensive portfolio of antibody production to further serve the biopharma market by offering both HEK293 with reduced turnaround times enabled by our Express Genes as well as the newly launched CHO cell line for Twist Express Antibodies," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. "By taking on the process of antibody development from sequence to protein, we meet the needs of therapeutic developers who currently make their own antibodies, a costly bottleneck in the discovery pipeline, providing them with a cost-effective, customizable, and scalable offering to support their research."

08:11 EDT Ovid Therapeutics announces eNeuro published studies on OV329 mechanism - Ovid Therapeutics announced that eNeuro, a peer-reviewed, open-access journal from the Society for Neuroscience published several preclinical studies validating OV329's mechanism of action and anti-convulsant properties. Sustained exposure to low doses of OV329 delivered reduced GABA-AT activity and increased GABA accumulation in mouse brains. Mice treated with OV329 at 5 mg/kg every 24 hours for six days showed significantly reduced GABA-AT activity in the brain to 62.6 +/- 4.4% of control. In parallel, treatment with OV329 significantly increased GABA levels to 134.0 +/- 7.2% of control as measured using liquid chromatography coupled with mass spectroscopy. Repeat, low doses of OV329 delivered synaptic and extra synaptic inhibition in mice suggesting it may provide sustained anti-convulsant activity. Mice consistently treated with a low dose of 0.5 mg/kg of OV329 over six days were shown to experience phasic and tonic inhibition as compared to placebo. These findings, which were measured by electrophysiological recordings, may differentiate OV329 from other anti-convulsant medicines and suggest the potential to provide broad inhibitory neurotransmission. Sustained doses of OV329 reduced the severity of status epilepticus and prevented development of benzodiazepine resistance in a mouse model with similarities to SE patients. OV329 was shown to have superior potency to the GABA-AT target than published results for vigabatrin. OV239 had an IC50 of 104.1 nM for GABA-AT, while the published IC50 for VGB was 183.8 microM.

08:09 EDT Syntec Optics builds higher volume manufacturing cells for LEO - Syntec Optics announced that it has successfully developed two different and scalable solutions that deliver higher weekly production volumes to meet demands for optics used in low earth orbit satellites and data centers. Syntec continues to receive orders for these two different lines of products in the newly entered communications end-market that utilize Syntec's broad capabilities, including ultra-high precision nano-machining, precision mechanicals, and replicative molded optics. Continuing orders demonstrate the growing demand for Syntec's advanced optics solutions in the low-earth orbit, LEO, satellite market. The increasing deployment of Artificial Intelligence is believed to drive higher demand for data center optical connectivity. Syntec has added more people and created an innovative, custom, and dedicated process for increased throughput.

08:08 EDT Horizon Aircraft appoints Phil Kelly as SVP, business development - New Horizon Aircraft announces that Phil Kelly has been appointed as Senior Vice President Business Development. Phil's illustrious career in aerospace spans four decades, from his strike fighter experience in flying Sea Harrier FA2 and Harrier GR7/9A aircraft to his last role as Head Carrier Strike and Maritime Aviation in the Develop directorate of NCHQ, where he led aircraft development for the UK Royal Navy and Royal Marines.

08:07 EDT MGM Resorts named as Proud Partner of the New York Yankees - MGM Resorts International announced a new partnership designating MGM Resorts as a "Proud Partner of the New York Yankees." The two organizations will collaborate to deliver exclusive VIP experiences to MGM Rewards members and baseball fans, including the opportunity to watch batting practice from the warning track and throw out a ceremonial first pitch at Yankee Stadium. MGM Resorts will also have brand placement at Yankee Stadium on LED signage, first and third base rotational signage, and its logo appearing on the back of the pitcher's mound during live local television broadcasts of select games.

08:06 EDT Enveric Biosciences issued patent by USPTO for drug candidate - Enveric Biosciences announced the expansion of protection for potential clinical indications for its EB-002 drug candidate through the issuance of Patent No. 11,945,778 by the United States Patent and Trademark Office. The company said, "We believe the US patent issuance significantly increases the Company's current intellectual property protection of EB-002 by adding methods of treatment that claim a broad field of brain neurological disorders. The methods of treatment intend to apply to neurological disorders such as sleep disorders, depression, substance-related disorders, and headaches. EB-002 is Enveric's next generation psilocin prodrug being developed for neuropsychiatric disorders, initially anxiety. EB-002 now has additional patent protection supporting the enhanced potential to both expand into additional neurological conditions and serve a broad range of patient populations."

08:05 EDT Aligos Therapeutics to host KOL event to discuss Phase 1b data of ALG-000184 - Aligos Therapeutics will host a virtual KOL event featuring Mark Sulkowski, MD, Johns Hopkins University School of Medicine, to discuss the unmet need and current treatment landscape for patients with chronic hepatitis B, positive data from the Phase 1b study of ALG-000184, development plans, and the chronic suppression regulatory pathway on Thursday, July 18, 2024 at 3:00pm ET/12:00pm PT. "We are pleased to be hosting this KOL event with Dr. Sulkowski, as we are excited to share the recent FDA feedback on the path forward to bring our best/first-in-class molecule to patients in need of better therapies," stated Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer at Aligos Therapeutics. "ALG-000184 monotherapy continues to show unprecedented reductions in all viral markers of CHB without viral breakthrough, with data 72 weeks that was recently presented at the EASL Congress 2024. The efficacy data to date has already demonstrated the potential for superiority compared to nucleos(t)ide analogs, reducing HBV DNA levels below 10 IU/mL in both HBeAg-positive and HBeAg-negative patients at Week 48. We look forward to providing additional details on the chronic suppression indication during the event."

08:05 EDT GCT Semiconductor and Kyocera team on 5G reference platform for CPE devices - GCT Semiconductor Holding announce a collaboration to develop a 5G reference platform for customer premise equipment CPE and fixed wireless access FWA devices. The 5G reference platform incorporates GCT's 5G chipset and Kyocera's 5G mmWave antenna module. The new platform will play a key role in the development of Kyocera's own products as well as GCT's rapid development of 5G mmWave CPE devices for GCT's 5G customers. "This collaboration will bring together first-class mmWave antenna technology with superior 4G and 5G expertise, combining advanced technologies to provide a total solution for Kyocera's product platform and GCT's 5G customers," says John Schlaefer, CEO of GCT Semiconductor. "We believe the new 5G reference platform will further strengthen GCT's position as a leader in the rapidly growing 5G mmWave CPE market." "We are dedicated to partnering with best-in-class technology experts such as GCT to develop the most reliable products on the market," says Masaaki Hori, Deputy General Manager of Corporate KWIC Division, Kyocera.

08:04 EDT Genasys announces new EVAC contract with Santa Barbara County - Genasys announced a new Genasys EVAC contract with Santa Barbara County. Santa Barbara joins 36 other California counties in deploying EVAC, a revolutionary, zone-based crisis response and alerting solution, to enhance the safety of residents and visitors during critical events. "EVAC has quickly become the crisis planning, evacuation modeling, and situational awareness solution of choice for first responders and emergency managers," said Richard Danforth, CEO of Genasys. "EVAC accelerates decision making time by identifying areas for protective action, enhances communication and collaboration with agencies during cross jurisdictional events, integrates and displays zone-based maps on county and municipal websites and apps, and significantly improves community awareness of evacuation planning efforts with real-time notifications and updates."

08:04 EDT Lisata Therapeutics announces preclinical results for certepetide - Lisata Therapeutics announces preclinical results for its investigational candidate, certepetide. The data, presented in a poster by Dr. Dan G. Duda of Massachusetts General Hospital at the 2024 Cholangiocarcinoma Foundation Annual Conference, showed that certepetide combined with standard-of-care chemotherapy and immunotherapy improved survival in mice with intrahepatic cholangiocarcinoma. These findings suggest potential benefits for human patients with this aggressive cancer and support advancing clinical development efforts for certepetide in intrahepatic cholangiocarcinoma.

08:02 EDT Oragenics develops new formulation for novel neurosteroid - Oragenics has developed a new formulation for its novel neurosteroid. Oragenics' lead drug candidate for concussion, ONP-002, is a new chemical entity designed to target the brain through delivery into the nasal cavity and onward to the brain. A Phase II study in concussed patients is being planned to assess safety and feasibility while analyzing the drug's effectiveness based on patient blood biomarker profiles and functional outcomes. Oragenics believes the nasal cavity provides access for Oragenics' novel neurosteroid formulation to enter the brain in minutes. Given the difficulty of getting neurosteroids into solution, unique formulations must be developed to achieve therapeutic levels. Oragenics believes that its recent work has increased the final dose levels significantly while also providing for improved intranasal drug adhesion and, thus, longer absorption times. Oragenics believes it has successfully completed an improved formulation of ONP-002 that should significantly increase the bioavailability of the intranasal drug formulation. The enhanced drug percentages in this novel formulation have been developed by Oragenics as part of its platform for acute-field delivery of the drug. Oragenics' newly developed intranasal drug formulation is intended to reduce the duration of initial concussion symptoms and prevent long-lasting symptoms that can be debilitating after a concussion.

08:02 EDT RTX's Raytheon awarded contract from U.S. Army - Raytheon, an RTX business, has been awarded a contract from the U.S. Army Futures Command Futures and Concepts Center to conduct theater level concept experimentation and mission analysis to support agile learning of the future battlefield. Under the contract, a Raytheon team will use its Rapid Campaign Analysis and Demonstration Environment, known as RCADE, to develop large-scale theater scenarios to help FCC leaders assess concepts of operations in a multi-domain conflict. Quantitative data and findings from the scenarios will help identify capabilities needed to succeed in future conflicts.

07:53 EDT Accenture acquires Cientra, terms undisclosed - Accenture has acquired Cientra, a silicon design and engineering services company, offering custom silicon solutions for global clients. The terms of the acquisition were not disclosed. Founded in 2015, Cientra is headquartered in New Jersey, U.S. and has offices in Frankfurt, Germany as well as in Bangalore, Hyderabad and New Delhi, India.

07:40 EDT Standard Motor to acquire Nissens Automotive for ~$388M in cash - Standard Motor Products announced it has reached a definitive agreement to acquire AX V Nissens III APS, a European manufacturer and distributor of aftermarket engine cooling and air conditioning products with a growing array of vehicle control technologies, for approximately $388M in cash from Nordic private equity firm Axcel and the Nissen family. Nissens has annual revenues of approximately $260M with a mid-teens EBITDA margin rate. The transaction values Nissens at approximately $388M, representing approximately 7.5x Adjusted EBITDA after factoring estimated run-rate cost synergies at the mid-point of $10M. The transaction is expected to be accretive to SMP's GAAP EPS in the first full year. The transaction is expected to be completed in the second half of 2024, and is subject to certain closing conditions, including receipt of applicable antitrust and other regulatory approvals.

07:33 EDT Longeveron announces U.S. FDA granted RMAT designation to Lomecel-B - Longeveron announced that the U.S. Food and Drug Administration, FDA, granted Regenerative Medicine Advanced Therapy, RMAT, designation to Lomecel-B for the treatment of mild Alzheimer's Disease. Lomecel-B is a proprietary, scalable, allogeneic cellular investigational therapy being evaluated across multiple indications, including Alzheimer's Disease, Aging-related Frailty and hypoplastic left heart syndrome. To the Company's knowledge based on publicly available information, Lomecel-B is the first cellular therapeutic candidate to receive RMAT designation for Alzheimer's Disease.

07:33 EDT Digital Realty acquires data center campus in Slough for $200M - Digital Realty announced the acquisition of a highly connected colocation data center in the Slough Trading Estate for $200M. The acquisition marks the company's entry into the west London submarket and complements existing colocation capabilities in the City and Docklands. The newly acquired campus features two individual data centers with a combined capacity of 15-megawatts, excellent connectivity, and room for future expansion. The Slough data center campus is an established hub for a community of 150+ customers, including a broad array of connectivity providers, technology companies, and financial services firms, utilizing over 2,000 cross connects.

07:32 EDT Kazia Therapeutics reports results from GBM-AGILE phase II/III study - Kazia Therapeutics announced results from GBM-AGILE, a phase II/III study that included an evaluation of paxalisib versus standard of care, or SOC, for patients with glioblastoma, or NCT03522298, a life-threatening brain cancer, where there is an urgent unmet need for new therapeutics. Kazia CEO, John Friend stated, "We are excited to have shown a 3.8 month improvement in overall survival, an approximate 33% improvement, for newly diagnosed unmethylated patients with GBM compared to the concurrent standard of care arm. Having comparable Overall Survival data across two independent studies is a compelling outcome in this difficult to treat glioblastoma population. We look forward to discussing possible approaches for an accelerated approval pathway for paxalisib with the FDA." A total of 313 newly diagnosed unmethylated patients and recurrent patients being treated at top US cancer hospitals were randomized in Stage 1 to either a paxalisib treatment arm or the SOC concurrent control arm from January 2021 to May 2022. The cumulative control arm was enrolled from July 2019 to May 2022. For the primary analysis the median Overall Survival was 14.77 months for paxalisib-treated NDU patients versus 13.84 months for cumulative SOC NDU patients.Full data including secondary endpoints from the paxalisib arm of the GBM AGILE study is expected to be presented at a scientific meeting later this year.

07:17 EDT Shell to invest in Ruwais LNG project in Abu Dhabi - Shell Overseas Holdings Limited, a subsidiary of Shell plc (SHEL), has signed an agreement to invest in the Abu Dhabi National Oil Company's, or ADNOC, Ruwais liquefied natural gas, or LNG, project in Abu Dhabi through a 10% participating interest. The Ruwais LNG project will consist of two 4.8 million metric tonnes per annum LNG liquefaction trains with a total capacity of 9.6 mmtpa. Shell, through its subsidiary Shell International Trading Middle East Limited FZE, has also signed an agreement to offtake 1 mmtpa of LNG produced by the project. ADNOC will hold a majority 60% share in the project and serve as the lead developer and operator of the facility, while Shell, BP (BP), Mitsui and TotalEnergies (TTE) will each hold 10%. "This investment decision builds on our long-standing partnership with ADNOC. In line with our strategy to create more value with less emissions, we are investing in additional LNG capacity and further growing our world-leading LNG portfolio, with energy-efficient and carbon-competitive projects," said Shell's Chief Executive Officer Wael Sawan.

07:15 EDT D-Wave's quantum workforce development initiative sees double digit growth in 1H - D-Wave Quantum announced that enrollment in its quantum training courses has experienced double-digit growth in the first six months of 2024, compared to the same period in 2023. Enrollment in the "Quantum Programming Core" course increased by 53%, and all total enrollments increased by 85%. This remarkable growth underscores a burgeoning global movement to train workers to keep pace with the rapidly increasing adoption of quantum computing. The urgency to meet increasing demand for quantum programming skills comes amid predictions that less than half of all projected quantum computing job openings will be filled by 2025, according to a McKinsey report. Reinforcing this trend, the demand for in-house quantum computing expertise is cited by businesses actively using quantum computing as a top hurdle to their success, according to a recent 2024 Hyperion Research survey commissioned by D-Wave. In addition, quantum workforce development is now included in nearly all government quantum programs across Australia, Canada, the European Union, Japan, the United Kingdom, and the United States, among others. "With rapidly increasing demand for quantum-ready talent and a shortage of quantum-trained workers, we're at a critical crossroads with quantum education," said Victoria Goliber, D-Wave's head of technical advising. "Our learning solutions foster an environment of experimentation and innovation that helps streamline and expedite skills training to prepare the workforce now in order to meet the growing need for quantum optimization capabilities."

07:13 EDT Diversified Energy to acquire natural gas properties from Crescent Pass - Diversified Energy Company announced the execution of a conditional purchase and sale agreement for the acquisition of high-working interest, operated natural gas properties and related facilities located within eastern Texas from Crescent Pass Energy. The Acquisition will be funded through a combination of the issuance of approximately 2.4 million new U.S. dollar-denominated ordinary shares direct to the Seller and a senior secured bank facility supported by the acquired assets, along with existing and expanded liquidity from the Company's recently increased borrowing capacity. The ordinary shares will be subject to a customary commercial lock-up agreement. The Company expects to close the Acquisition in the third quarter of 2024. Acquisition Highlights: Purchase price of $106 million before anticipated, customary purchase price adjustments; Estimated Net Purchase Price of $100 million; Anticipated close during the third quarter of 2024; Net purchase price represents a PV-20 valuation; Current net production of 38 MMcfepd with low annual declines of ~9%; Complements industry-leading corporate declines and capital intensity; Significantly gas-weighted production with ~92% gas volumes; Attractively priced at $2,651 per flowing Mcfe; Provides opportunities for additional cost efficiencies; Estimated NTM EBITDA of ~$26 million representing a 3.8x purchase multiple; PDP Reserves of ~170 Bcfe with PV-10 of $155 million; Assets are contiguous with Diversified's existing East Texas assets; Proximity to existing assets creates immediate line of sight to future operating efficiencies; Includes ~170,000 acres of commercially attractive leasehold in both East Texas and the Freestone Trend.

07:11 EDT Tilray announces Good Supply brand released updated lineup - Tilray Brands announced that its Good Supply cannabis brand has released its updated lineup of 1G 510 vapes with potency featuring a wide selection of the best flavors to choose from for 710 and beyond.

07:09 EDT United Therapeutics announces full enrollment of TETON 2 study - United Therapeutics announced full enrollment of the TETON 2 study evaluating the use of Tyvaso inhalation solution for the treatment of idiopathic pulmonary fibrosis, or IPF.

07:09 EDT Green Thumb Industries' RISE Dispensaries continues Florida expansion - RISE Dispensaries, a cannabis retail chain owned by Green Thumb Industries, announced the upcoming openings of RISE Dispensary Tallahassee on Mahan, located at 2459 Mahan Drive, and RISE Dispensary Tallahassee on Tennessee, located at 1412 W Tennessee Street, on July 12. The two locations expand the Company's retail footprint to 19 Florida locations and 96 nationwide. Beginning July 12, RISE Tallahassee on Mahan and RISE Tallahassee on Tennessee will introduce RISE Dispensaries' products and service to Florida's capital city, with both locations to be open Monday through Saturday from 9 a.m. to 8 p.m. and Sunday from 11 a.m. to 6 p.m.

07:08 EDT Unicycive announces initial results from patient reported outcome survey on OLC - Unicycive Therapeutics announced the initial results from the patient reported outcome survey conducted during the UNI-OLC-201 pivotal clinical trial. The top-line results from the oxylanthanum carbonate trial in patients with hyperphosphatemia who have chronic kidney disease on dialysis were reported on June 25, 2024. The patient reported outcomes are being evaluated from a satisfaction questionnaire that was a pre-specified exploratory objective of the study. The questionnaire surveyed patients in the UNI-OLC-201 trial to assess characteristics of their current phosphate binder as compared to OLC after switching medications. The questions included patient satisfaction, ease of use, and preferred therapy and were taken at the start and conclusion of the study. In the survey, OLC consistently outperformed the other phosphate binders in all categories: 79% of patients preferred OLC while 18% preferred their prior therapy, 98% of patients said that OLC was easy to take compared to 55% for their prior therapy, 89% of patients said they were satisfied with OLC while 49% were satisfied with their prior therapy. Patients screened to enter the trial were taking the following phosphate binder therapies: 52% Renvela, 19% PhosLo, 13% Velphoro, and 1% Other. Once patients were enrolled into the trial, they went through a washout period for two weeks to clear their current phosphate binder from the body. Preferred Therapy: In response to the question: Based on your experience in this clinical trial, do you prefer your current phosphate binder or OLC, 79% preferred OLC, 18% preferred their prior phosphate binder, and 3% preferred neither. Ease of Use: In the trial, the median patient pill burden on OLC was reduced by half compared to their prior phosphate binder therapy. The pill burden on prior therapy at screening was a median of 6 pills per day. On OLC, the pill burden at the end of the study was a median of 3 pills per day. In response to the question: My current phosphate binding medication is easy to take, 55% of patients agreed, 41% disagreed, and 4% neither agreed nor disagreed. In response to the question: Oxylanthanum carbonate is easy to take, 98% of patients agreed, 1% disagreed, and 1% neither agreed nor disagreed. Patient Satisfaction: At screening, less than half of the patients in the study agreed with the statement, I am satisfied with my current phosphate binder medication. At the end of the study and after switching to OLC, 89% of patients agreed with the statement, I am satisfied with oxylanthanum carbonate. Only 6% expressed dissatisfaction with OLC.

07:06 EDT Amylyx acquires Phase 3-ready avexitide from Eiger for $35.1M plus - Amylyx Pharmaceuticals announced the acquisition of avexitide from Eiger BioPharmaceuticals ... Avexitide has been studied for the potential treatment of hyperinsulinemic hypoglycemia to date. "Since Amylyx was founded, we have been guided by a rigorous approach to our science to bring potential treatments to communities with high unmet needs. When we reviewed all the compelling data supporting avexitide, it clearly aligned with our strategic scientific criteria, expertise, and community values, and we are excited to build upon the important work done to date to study this asset," said Joshua Cohen and Justin Klee, Co-CEOs of Amylyx. Avexitide is an investigational, first-in-class glucagon-like peptide-1 GLP-1 receptor antagonist that has been evaluated in five clinical trials for post-bariatric hypoglycemia PBH and has also been studied in congenital hyperinsulinism , two indications characterized by hyperinsulinemic hypoglycemia. The U.S. Food and Drug Administration has granted avexitide Breakthrough Therapy Designation for both indications, Rare Pediatric Disease Designation in congenital HI, and Orphan Drug Designation for the treatment of hyperinsulinemic hypoglycemia . Avexitide is designed to bind to the GLP-1 receptor on pancreatic islet beta cells and block the effect of GLP-1 to mitigate hypoglycemia by decreasing insulin secretion and stabilizing glucose levels. In PBH, excessive GLP-1 can lead to the hypersecretion of insulin and subsequent severe hypoglycemic events, including autonomic and neuroglycopenic symptoms if left unaddressed.On July 9, Amylyx completed the acquisition of substantially all of the rights, title and interests in, to and under those assets and interests used by the seller in the development, manufacture and commercialization of avexitide from Eiger for $35.1M plus the aggregate amount of determined cure costs and assumed liabilities. As part of the transaction, Amylyx assumed certain contractual obligations from Eiger, including a 3% royalty on future sales of avexitide in PBH, if approved, to certain academic institutions.

07:04 EDT Dragonfly Energy strengthens presence in Canada, partners with Fraserway RV - Dragonfly Energy announces the strengthening of its presence in the Canadian market through a strategic partnership with Fraserway RV, Canada's largest coast-to-coast RV dealer group. This collaboration expands Dragonfly Energy's footprint in North America, building on its continued growth in the RV industry. Fraserway RV dealerships across Canada will now stock and install Battle Born Batteries as a customer upgrade option. This expansion within the Canadian marketplace by Dragonfly Energy comes at a time when the country is seeing an increase in camping overall, with 67 percent of all Canadian households identifying as campers and outdoor hospitality participants in 2023, according to a recent Kampgrounds of America.

07:03 EDT Okyo Pharma announces new data from OK-101 Phase 2 trial - OKYO Pharma announced promising new categorical data analyses from the recent OK-101 Phase 2 trial in DED patients. These analyses have identified conjunctival staining and ocular pain as the highest potential "sign" and "symptom" co-primary endpoints to be explored in the next DED trial of OK-101. Categorical Analysis Details: Recently released data from the Phase 2, randomized, double-masked, placebo-controlled trial evaluating the safety and efficacy of OK-101 ophthalmic solution in subjects with DED were analyzed by categorical evaluation of the data set and responder-rate analyses. Importantly, the data set for the analysis utilized the full Intent-to-Treat population of 240 patients. Key findings evaluated responder rates for those patients demonstrating at least 12.5% reduction in conjunctival sum staining combined with at least a 30% reduction in the observed symptom as measured by improvement from baseline through the last study visit at Day 85. Notably, the number of patients showing both a reduction in conjunctival sum staining and in the pain symptom in the OK-101-treated group was 34.2% compared to 20.3% in the placebo-treated group, a 68% improvement. Similarly, the number of patients with reduction in conjunctival sum staining and burning/stinging symptoms were also numerically higher in the OK-101-treated group compared to the placebo-treated group, with a 62% improvement.

07:03 EDT Mercury enters agreement with U.S. Navy to advance sensor processing tech - Mercury Systems announced an agreement with the U.S. Navy to advance sensor processing technologies that will allow radar and electronic warfare capabilities to be designed on much shorter timelines. For decades, increasing system and software complexity has extended the timelines for developing and fielding military platforms. The Office of Naval Research's Open Rapid Chipletized Approach program aims to reduce the time needed to design edge processing solutions by increasing the modularity of components at the chip level. Under a $13.2 million contract, Mercury will develop a next-generation RF System-in-Package that integrates the latest commercial chips from major semiconductor providers within a smaller and lighter footprint. This work will build on Mercury's RFS1140 SiP, which integrates an AMD Versal FPGA, Jariet Electra-MA high-speed data converters, and Micron memory for a truly advanced solution to support sensor processing.

06:46 EDT Virgin Galactic completes new new manufacturing facility in Phoenix - Virgin Galactic Holdings announced the completion of its new manufacturing facility in Phoenix, Arizona, where final assembly of its next-generation Delta spaceships is scheduled to take place starting in Q1 2025. An initial team of Virgin Galactic technical operations and manufacturing personnel has begun preparing the facility to receive and install tooling, expected to arrive in Q4. The facility will then begin to receive major subassemblies, including the wing, the fuselage, and the feathering system next year, as the team scales to build the first two ships of the Delta fleet. Once ground testing in Phoenix is complete, Virgin Galactic's mothership will ferry completed spaceships to Spaceport America, New Mexico for flight test ahead of commercial operations, which are expected to begin in 2026. The multiuse facility includes two hangars equipped with multiple bays, designed for maximum flexibility in building and testing space vehicles. Work at the facility will be supported by the Company's digital twin technology, which enables seamless integration between Virgin Galactic and suppliers through real-time collaboration, promoting strong governance and increased efficiency and reliability. Virgin Galactic's Delta spaceships will seat up to six private passengers, and each is expected to be capable of flying up to eight missions per month, dramatically increasing access to space.

06:06 EDT Vertical Aerospace receives further Design Organisation Approval from UK CAA - Vertical Aerospace announced that the scope of its Design Organisation Approval, or DOA, has been expanded by the UK Civil Aviation Authority, CAA. The scope extension enables Vertical's own engineers to sign off compliance of an increasing number of technical areas, including further areas related to the flight control, avionics and electrical systems. Expanding Vertical's capacity to carry out certification activities streamlines the certification process. This shows further confidence from the CAA that Vertical has the in-house capability to obtain certification for the VX4 aircraft to the highest aviation safety standards, with safety targets the same as those that large commercial airliners adhere to.

06:02 EDT Carvana launches streamlined shopping, checkout for used EV buyers - Carvana announced the launch of new features that make shopping for and buying a used electric vehicle or plug-in hybrid easier and more accessible for its customers. The streamlined process highlights vehicles that qualify for the Clean Vehicle Tax Credit in the search experience and allows eligible customers to apply the up to $4,000 in savings from the credit at checkout. Available now, Carvana's automated system checks vehicle eligibility and applies the Clean Vehicle Tax Credit to the purchase at checkout for eligible customers who elect to transfer their credit to Carvana. Rather than waiting for a lower tax bill next year, customers can now seamlessly access up-front savings of up to $4,000 on the price of the vehicle. These savings also automatically flow through to eligible customers' financing terms.

05:22 EDT Rio Tinto contributes A$40M towards Paraburdoo, Tom Price Hospitals - Rio Tinto will contribute A$20M to the Western Australian Government towards the major redevelopment of the Paraburdoo Hospital, in the state's Pilbara region. The partnership will see the ageing Paraburdoo Hospital upgraded with contemporary purpose-built facilities to support medical services for the local community, including new rooms for the GP. Rio Tinto's contribution to the Paraburdoo Hospital will come from the company's A$250M commitment to the Western Australian Government's Resources Community Investment Initiative, or RCII. The major redevelopment of the Paraburdoo Hospital is the first project through the RCII to receive funding. The project will be packaged together with Rio Tinto's previous A$20M commitment to a new Tom Price Hospital, as part of a procurement approach by the State Government to create a larger package of work that is more attractive to potential contractors.

05:15 EDT Nokia selected by Norlys to provide mobile core network, managed services - Nokia announced that it has been selected by Norlys, the owner of Telia Denmark and the largest integrated energy and telecommunications operator in Denmark, to provide its mobile core network and managed services. The deal, combined with a RAN contract signed with Nokia in 2021, will enhance Norlys' mobile network performance and reliability. The deal covers the deployment of Nokia's 4G/5G packet core, and IMS and SDM solutions, which will support voice and data services for Norlys subscribers.